Reducing the frequency of respiratory tract infections in severe neurological disorders by inhaled antibiotics: a retrospective data analysis.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
06
09
2018
accepted:
14
05
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
epublish
Résumé
In patients with severe neurological impairment, recurrent respiratory tract infections frequently occur as a result of impaired clearance of airway secretions and microbial airway colonisation. We hypothesised that inhaled antibiotic therapy may improve the morbidity of these patients. A retrospective data analysis of 20 patients (11 nontracheotomised and nine tracheotomised) with neurological impairment and microbial airway colonisation was carried out at a children's university hospital. Two questionnaires that asked about the number of respiratory tract infections, antibiotic therapies and hospitalisations were distributed to the patients/caregivers: a first questionnaire representing the 12 months prior to the initiation of inhaled antibiotics and a second questionnaire describing the first 12 months under therapy. During the first 12 months of therapy, the frequency of respiratory tract infections among all participants was reduced from a mean of 6.8 episodes (median (interquartile range (IQR)) 6.0 (4.0-10.0) episodes) to a mean of 2.5 episodes (median (IQR) 2.0 (1.0-3.0) episodes; p<0.001). In addition, a significant decrease of systemic antibiotic therapies (mean 7.7, median (IQR) 6.0 (4.0-10.0) The presented data suggest that inhaled antibiotics might play a role in treating recurrent respiratory tract infections in neuromuscular diseases.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with severe neurological impairment, recurrent respiratory tract infections frequently occur as a result of impaired clearance of airway secretions and microbial airway colonisation. We hypothesised that inhaled antibiotic therapy may improve the morbidity of these patients.
METHODS
METHODS
A retrospective data analysis of 20 patients (11 nontracheotomised and nine tracheotomised) with neurological impairment and microbial airway colonisation was carried out at a children's university hospital. Two questionnaires that asked about the number of respiratory tract infections, antibiotic therapies and hospitalisations were distributed to the patients/caregivers: a first questionnaire representing the 12 months prior to the initiation of inhaled antibiotics and a second questionnaire describing the first 12 months under therapy.
RESULTS
RESULTS
During the first 12 months of therapy, the frequency of respiratory tract infections among all participants was reduced from a mean of 6.8 episodes (median (interquartile range (IQR)) 6.0 (4.0-10.0) episodes) to a mean of 2.5 episodes (median (IQR) 2.0 (1.0-3.0) episodes; p<0.001). In addition, a significant decrease of systemic antibiotic therapies (mean 7.7, median (IQR) 6.0 (4.0-10.0)
CONCLUSIONS
CONCLUSIONS
The presented data suggest that inhaled antibiotics might play a role in treating recurrent respiratory tract infections in neuromuscular diseases.
Identifiants
pubmed: 31360698
doi: 10.1183/23120541.00149-2018
pii: 00149-2018
pmc: PMC6646963
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Conflict of interest: M. Eckerland has nothing to disclose. Conflict of interest: C. Bock has nothing to disclose. Conflict of interest: M. Olivier has nothing to disclose. Conflict of interest: L. Pichlmaier has nothing to disclose. Conflict of interest: M. Steindor has nothing to disclose. Conflict of interest: F. Stehling has nothing to disclose.
Références
Pediatr Pulmonol. 2001 Oct;32(4):314-27
pubmed: 11568993
Pediatr Pulmonol. 2002 Aug;34(2):91-100
pubmed: 12112774
Thorax. 2002 Dec;57(12):1015-20
pubmed: 12454294
Neuromuscul Disord. 2002 Dec;12(10):926-9
pubmed: 12467747
Pediatr Pulmonol. 2004 Apr;37(4):356-61
pubmed: 15022133
Am J Respir Crit Care Med. 2004 Aug 15;170(4):456-65
pubmed: 15302625
J Cyst Fibros. 2004 Jun;3(2):67-91
pubmed: 15463891
Neuromuscul Disord. 2006 May;16(5):325-8
pubmed: 16621559
Pediatr Pulmonol. 2008 Jan;43(1):67-71
pubmed: 18041752
Pediatr Crit Care Med. 2009 Mar;10(2):222-6
pubmed: 19057452
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD001021
pubmed: 21412868
Eur J Pediatr. 2012 Mar;171(3):409-14
pubmed: 21932013
J Pediatr Rehabil Med. 2011;4(2):155-8
pubmed: 21955974
Eur Respir J. 2014 Aug;44(2):382-93
pubmed: 24925920
Laryngoscope. 2015 Feb;125(2):462-8
pubmed: 24986601
Am J Crit Care. 2014 Nov;23(6):e80-7
pubmed: 25362678
PLoS One. 2015 May 01;10(5):e0125839
pubmed: 25933065
Respir Care. 2016 Apr;61(4):447-52
pubmed: 26670471
Ital J Pediatr. 2016 Jan 20;42:7
pubmed: 26791415
Lung. 2016 Apr;194(2):307-14
pubmed: 26883134
Respirology. 2016 Oct;21(7):1285-91
pubmed: 27221716
Acta Paediatr. 2016 Dec;105(12):e588-e592
pubmed: 27387674
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823
pubmed: 27748623
Respirology. 2017 Jul;22(5):1035-1036
pubmed: 28370913
Respirology. 2017 Jul;22(5):1036
pubmed: 28370960
Cochrane Database Syst Rev. 2017 Apr 25;4:CD004197
pubmed: 28440853
Pediatr Pulmonol. 2017 Sep;52(9):1212-1218
pubmed: 28440922
Respir Care. 2017 Jun;62(6):826-848
pubmed: 28546380
J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):121-138
pubmed: 29077527
Respir Med. 2018 Mar;136:98-110
pubmed: 29501255
J Cyst Fibros. 2018 Mar;17(2):153-178
pubmed: 29506920
Pediatr Pulmonol. 2018 Sep;53(9):1269-1275
pubmed: 29968973
Am Rev Respir Dis. 1988 Jul;138(1):5-7
pubmed: 3202399
Pediatr Pulmonol. 1995 Jan;19(1):10-5
pubmed: 7675552
N Engl J Med. 1993 Jun 17;328(24):1740-6
pubmed: 8497284
Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111-8
pubmed: 8520783
Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):659-64
pubmed: 9279255
Chest. 1998 Jan;113(1):77-85
pubmed: 9440572
N Engl J Med. 1999 Jan 7;340(1):23-30
pubmed: 9878641